MT1-MMP releases latent TGF-β1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1

Experimental Cell Research

Volumn 314, Issue 13, 2008, Pages 2501-2514

  Tatti, Olga ^a   Vehviläinen, Piia ^a   Lehti, Kaisa ^a   Keski Oja, Jorma ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

ECM; Endothelial cells; LTBP; MT1 MMP; TGF

Indexed keywords

INTERSTITIAL COLLAGENASE; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA1 BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PLASMIN; PROTEIN KINASE C; SHORT HAIRPIN RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UROKINASE;

ARTICLE; CELL ACTIVITY; CELL MIGRATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION;

EID: 47349086991     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.05.018     Document Type: Article

References (67)

1. Mazzieri R., Jurukovski V., Obata H., Sung J., Platt A., Annes E., Karaman-Jurukovska N., Gleizes P.E., and Rifkin D.B. Expression of truncated latent TGF-beta-binding protein modulates TGF-beta signaling. J. Cell. Sci. 118 (2005) 2177-2187
2. ten Dijke P., and Arthur H.M. Extracellular control of TGFbeta signalling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 857-869
3. McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., Helmbold E.A., Markel D.S., McKinnon W.C., and Murrell J. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8 (1994) 345-351
4. Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I., Yoon S.J., Stenzel T.T., Speer M., Pericak-Vance M.A., Diamond A., Guttmacher A.E., Jackson C.E., Attisano L., Kucherlapati R., Porteous M.E., and Marchuk D.A. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 13 (1996) 189-195
5. Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N., Morisaki T., Allard D., Varret M., Claustres M., Morisaki H., Ihara M., Kinoshita A., Yoshiura K., Junien C., Kajii T., Jondeau G., Ohta T., Kishino T., Furukawa Y., Nakamura Y., Niikawa N., Boileau C., and Matsumoto N. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat. Genet. 36 (2004) 855-860
6. Habashi J.P., Judge D.P., Holm T.M., Cohn R.D., Loeys B.L., Cooper T.K., Myers L., Klein E.C., Liu G., Calvi C., Podowski M., Neptune E.R., Halushka M.K., Bedja D., Gabrielson K., Rifkin D.B., Carta L., Ramirez F., Huso D.L., and Dietz H.C. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312 (2006) 117-121
7. Neptune E.R., Frischmeyer P.A., Arking D.E., Myers L., Bunton T.E., Gayraud B., Ramirez F., Sakai L.Y., and Dietz H.C. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33 (2003) 407-411
8. Zacchigna L., Vecchione C., Notte A., Cordenonsi M., Dupont S., Maretto S., Cifelli G., Ferrari A., Maffei A., Fabbro C., Braghetta P., Marino G., Selvetella G., Aretini A., Colonnese C., Bettarini U., Russo G., Soligo S., Adorno M., Bonaldo P., Volpin D., Piccolo S., Lembo G., and Bressan G.M. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 124 (2006) 929-942
9. Chaudhry S.S., Cain S.A., Morgan A., Dallas S.L., Shuttleworth C.A., and Kielty C.M. Fibrillin-1 regulates the bioavailability of TGFbeta1. J. Cell Biol. 176 (2007) 355-367
10. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., and ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 21 (2002) 1743-1753
11. Pepper M.S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 8 (1997) 21-43
12. Pepper M.S., Vassalli J.D., Orci L., and Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp. Cell Res. 204 (1993) 356-363
13. Ito N., Kawata S., Tamura S., Shirai Y., Kiso S., Tsushima H., and Matsuzawa Y. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett. 89 (1995) 45-48
14. Ueki N., Nakazato M., Ohkawa T., Ikeda T., Amuro Y., Hada T., and Higashino K. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta. 1137 (1992) 189-196
15. Stearns M.E., Garcia F.U., Fudge K., Rhim J., and Wang M. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin. Cancer Res. 5 (1999) 711-720
16. Taipale J., Lohi J., Saarinen J., Kovanen P.T., and Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 270 (1995) 4689-4696
17. Miyazono K., Olofsson A., Colosetti P., and Heldin C.H. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 10 (1991) 1091-1101
18. Taipale J., Miyazono K., Heldin C.H., and Keski-Oja J. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J. Cell Biol. 124 (1994) 171-181
19. Hyytiainen M., Penttinen C., and Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit. Rev. Clin. Lab. Sci. 41 (2004) 233-264
20. Koli K., Hyytiainen M., Ryynanen M.J., and Keski-Oja J. Sequential deposition of latent TGF-beta binding proteins (LTBPs) during formation of the extracellular matrix in human lung fibroblasts. Exp. Cell Res. 310 (2005) 370-382
21. Gibson M.A., Hatzinikolas G., Davis E.C., Baker E., Sutherland G.R., and Mecham R.P. Bovine latent transforming growth factor beta 1-binding protein 2: molecular cloning, identification of tissue isoforms, and immunolocalization to elastin-associated microfibrils. Mol. Cell. Biol. 15 (1995) 6932-6942
22. Saharinen J., and Keski-Oja J. Specific sequence motif of 8-cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol. Biol. Cell. 11 (2000) 2691-2704
23. Taipale J., Koli K., and Keski-Oja J. Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J. Biol. Chem. 267 (1992) 25378-25384
24. Dallas S.L., Rosser J.L., Mundy G.R., and Bonewald L.F. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277 (2002) 21352-21360
25. Munger J.S., Harpel J.G., Gleizes P.E., Mazzieri R., Nunes I., and Rifkin D.B. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 51 (1997) 1376-1382
26. Annes J.P., Munger J.S., and Rifkin D.B. Making sense of latent TGFbeta activation. J. Cell. Sci. 116 (2003) 217-224
27. Solovyan V.T., and Keski-Oja J. Apoptosis of human endothelial cells is accompanied by proteolytic processing of latent TGF-beta binding proteins and activation of TGF-beta. Cell Death Differ. 12 (2005) 815-826
28. Sato Y., Okada F., Abe M., Seguchi T., Kuwano M., Sato S., Furuya A., Hanai N., and Tamaoki T. The mechanism for the activation of latent TGF-beta during co-culture of endothelial cells and smooth muscle cells: Cell-type specific targeting of latent TGF-beta to smooth muscle cells. J. Cell Biol. 123 (1993) 1249-1254
29. Ge G., and Greenspan D.S. BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J. Cell Biol. 175 (2006) 111-120
30. Hyytiainen M., Taipale J., Heldin C.H., and Keski-Oja J. Recombinant latent transforming growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release. J. Biol. Chem. 273 (1998) 20669-20676
31. Romero L.I., Zhang D.N., Herron G.S., and Karasek M.A. Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. J. Cell. Physiol. 173 (1997) 84-92
32. Karasek M.A. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease?. Med. Hypotheses (2006)
33. Montesano R., Orci L., and Vassalli P. Human endothelial cell cultures: phenotypic modulation by leukocyte interleukins. J. Cell. Physiol. 122 (1985) 424-434
34. Bujan J., Gimeno M.J., Prieto A., Pascual G., Bellon J.M., and Alvarez-Mon M. Modulation of PECAM-1 (CD31) expression in human endothelial cells: effect of IFNgamma and IL-10. J. Vasc. Res. 36 (1999) 106-113
35. Saharinen J., Taipale J., Monni O., and Keski-Oja J. Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J. Biol. Chem. 273 (1998) 18459-18469
36. Penttinen C., Saharinen J., Weikkolainen K., Hyytiainen M., and Keski-Oja J. Secretion of human latent TGF-beta-binding protein-3 (LTBP-3) is dependent on co-expression of TGF-beta. J. Cell. Sci. 115 (2002) 3457-3468
37. Moren A., Olofsson A., Stenman G., Sahlin P., Kanzaki T., Claesson-Welsh L., ten Dijke P., Miyazono K., and Heldin C.H. Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein. J. Biol. Chem. 269 (1994) 32469-32478
38. Ilan N., Mahooti S., and Madri J.A. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J. Cell. Sci. 111 Pt 24 (1998) 3621-3631
39. Taylor C.J., Motamed K., and Lilly B. Protein kinase C and downstream signaling pathways in a three-dimensional model of phorbol ester-induced angiogenesis. Angiogenesis 9 (2006) 39-51
40. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14 (2000) 163-176
41. Lohi J., Lehti K., Westermarck J., Kahari V.M., and Keski-Oja J. Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur. J. Biochem. 239 (1996) 239-247
42. Monea S., Lehti K., Keski-Oja J., and Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J. Cell. Physiol. 192 (2002) 160-170
43. Taylor K.L., Henderson A.M., and Hughes C.C. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc. Res. 64 (2002) 372-383
44. Herren B., Raines E.W., and Ross R. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J. 11 (1997) 173-180
45. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., and Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
46. Roy R., Zhang B., and Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Exp. Cell Res. 312 (2006) 608-622
47. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Sci. 115 (2002) 3719-3727
48. van Hinsbergh V.W., Engelse M.A., and Quax P.H. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 716-728
49. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1104-1117
50. Blasi F., and Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3 (2002) 932-943
51. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., and Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000) 737-744
52. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., and Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169 (2005) 681-691
53. Lehti K., Lohi J., Valtanen H., and Keski-Oja J. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem. J. 334 Pt 2 (1998) 345-353
54. Keski-Oja J., Shoyab M., De Larco J.E., and Todaro G.J. Rapid release of fibronectin from human lung fibroblasts by biologically active phorbol esters. Int. J. Cancer. 24 (1979) 218-224
55. Chun T.H., Sabeh F., Ota I., Murphy H., McDonagh K.T., Holmbeck K., Birkedal-Hansen H., Allen E.D., and Weiss S.J. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol. 167 (2004) 757-767
56. Yana I., Sagara H., Takaki S., Takatsu K., Nakamura K., Nakao K., Katsuki M., Taniguchi S., Aoki T., Sato H., Weiss S.J., and Seiki M. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J. Cell. Sci. 120 (2007) 1607-1614
57. Pei D., and Weiss S.J. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J. Biol. Chem. 271 (1996) 9135-9140
58. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 194 (2003) 1-11
59. Seiki M., Koshikawa N., and Yana I. Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Metastasis Rev. 22 (2003) 129-143
60. Takino T., Miyamori H., Watanabe Y., Yoshioka K., Seiki M., and Sato H. Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res. 64 (2004) 1044-1049
61. Saunders W.B., Bohnsack B.L., Faske J.B., Anthis N.J., Bayless K.J., Hirschi K.K., and Davis G.E. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J. Cell Biol. 175 (2006) 179-191
62. Karsdal M.A., Larsen L., Engsig M.T., Lou H., Ferreras M., Lochter A., Delaisse J.M., and Foged N.T. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J. Biol. Chem. 277 (2002) 44061-44067
63. Araya J., Cambier S., Morris A., Finkbeiner W., and Nishimura S.L. Integrin-mediated transforming growth factor-beta activation regulates homeostasis of the pulmonary epithelial-mesenchymal trophic unit. Am. J. Pathol. 169 (2006) 405-415
64. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., and Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22 (2001) 153-183
65. Pedram A., Razandi M., and Levin E.R. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J. Biol. Chem. 273 (1998) 26722-26728
66. Steinle J.J., Meininger C.J., Chowdhury U., Wu G., and Granger H.J. Role of ephrin B2 in human retinal endothelial cell proliferation and migration. Cell. Signal. 15 (2003) 1011-1017
67. Meng X.W., Heldebrant M.P., and Kaufmann S.H. Phorbol 12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting recruitment of fas-associated polypeptide with death domain. J. Biol. Chem. 277 (2002) 3776-3783